Certain cancer therapies provide better patient outcomes and fewer side effects than broad-based chemotherapy. But an individual’s response to a given treatment often depends on the tumor’s genomic profile.
For oncologists, Guardant360 provides comprehensive genomic results from a simple blood draw in approximately seven days, helping them move beyond the limitations of tissue biopsies to match patients with the best treatments. Obtaining clinically relevant genomic information through a blood draw helps them avoid an additional tissue or surgical biopsy and moves beyond the limitations of tissue specimens. Guardant360 covers all genes recommended for profiling by the National Comprehensive Cancer Network, including the 73 genes most relevant to clinical care.
Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists and all 27 National Comprehensive Cancer Network Centers.
If you are a healthcare provider looking for information about Guardant360, please visit our product website.